UBS Group
TOVX icon

UBS Group’s Theriva Biologics TOVX Stock Holding History

UBS Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.2K Buy
225,624
+34,214
+18% +$6.74K ﹤0.01% 7450
2025
Q4 		$40.2K Buy
191,410
+168,497
+735% +$49.8K ﹤0.01% 7342
2025
Q3 		$9.28K Buy
22,913
+22,912
+2,291,200% +$9.91K ﹤0.01% 8612
2025
Q2 		$0 Sell
1
-7,850
-100% -$6.37K ﹤0.01% 10828
2025
Q1 		$8.64K Sell
7,851
-8,555
-52% -$12K ﹤0.01% 8739
2024
Q4 		$28.7K Sell
16,406
-1,445
-8% -$2.11K ﹤0.01% 7639
2024
Q3 		$24.6K Buy
+17,851
New +$87.1K ﹤0.01% 7248
2024
Q2 		– Hold
0
– – – 9439
2024
Q1 		– Hold
0
– – – 9213
2023
Q4 		– Hold
0
– – – 9210
2023
Q3 		– Sell
-237
Closed -$5.93K – 9970
2023
Q2 		$5.93K Buy
+237
New +$4.17K ﹤0.01% 7417
2023
Q1 		– Sell
-201
Closed -$2.31K – 10379
2022
Q4 		$2.31K Sell
201
-70
-26% -$1.27K ﹤0.01% 9702
2022
Q3 		$7K Buy
271
+255
+1,594% +$9.79K ﹤0.01% 8907
2022
Q2 		$1K Sell
16
-303
-95% -$17.3K ﹤0.01% 9968
2022
Q1 		$23K Sell
319
-71
-18% -$4.84K ﹤0.01% 7305
2021
Q4 		$26K Buy
390
+180
+86% +$17K ﹤0.01% 7550
2021
Q3 		$24K Buy
+210
New +$26.1K ﹤0.01% 6980
2021
Q2 		– Sell
-2,308
Closed -$331K – 9826
2021
Q1 		$393K Buy
+2,308
New +$456K ﹤0.01% 5050
2020
Q4 		– Hold
0
– – – 8766
2020
Q3 		– Sell
-101
Closed -$13.5K – 8412
2020
Q2 		$13K Sell
101
-328
-76% -$31.3K ﹤0.01% 6848
2020
Q1 		$34K Buy
429
+428
+42,800% +$48.7K ﹤0.01% 6126
2019
Q4 		$0 Sell
1
-109
-99% -$11.6K ﹤0.01% 8413
2019
Q3 		$12K Buy
110
+108
+5,400% +$13K ﹤0.01% 7060
2019
Q2 		$0 Sell
2
-14
-88% -$2.01K ﹤0.01% 8161
2019
Q1 		$2K Sell
16
-79
-83% -$13.1K ﹤0.01% 7469
2018
Q4 		$13K Buy
95
+92
+3,067% +$21.8K ﹤0.01% 7104
2018
Q3 		$2K Sell
3
-16
-84% -$17.7K ﹤0.01% 7754
2018
Q2 		$39K Sell
19
-6
-24% -$13.8K ﹤0.01% 6195
2018
Q1 		$69K Buy
25
+5
+25% +$19K ﹤0.01% 5484
2017
Q4 		$88K Sell
20
-13
-39% -$81.2K ﹤0.01% 5450
2017
Q3 		$267K Buy
33
+10
+43% +$57.8K ﹤0.01% 4659
2017
Q2 		$117K Sell
23
-1
-4% -$4.98K ﹤0.01% 5078
2017
Q1 		$135K Buy
24
+2
+9% +$14K ﹤0.01% 4903
2016
Q4 		$148K Buy
22
+6
+38% +$61.6K ﹤0.01% 5001
2016
Q3 		$243K Hold
16
– – ﹤0.01% 4415
2016
Q2 		$255K Sell
16
-17
-52% -$320K ﹤0.01% 4383
2016
Q1 		$680K Buy
33
+26
+371% +$391K ﹤0.01% 3547
2015
Q4 		$138K Buy
7
+1
+17% +$21.2K ﹤0.01% 4962
2015
Q3 		$118K Buy
+6
New +$148K ﹤0.01% 5087
2015
Q2 		– Sell
-1
Closed -$14K – 8826
2015
Q1 		$14K Sell
1
-1
-50% -$17.9K ﹤0.01% 7362
2014
Q4 		$21K Buy
+2
New +$26.9K ﹤0.01% 7611

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's TOVX Position: Q1 2026 in Review

UBS Group increased its Theriva Biologics (TOVX) stake by 18% in Q1 2026, buying an estimated $6.74K and bringing the position to 225,624 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #7450.

UBS Group first reported a position in TOVX in Q4 2014 and has held it in 37 quarters since. The position peaked at $680K in Q1 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • UBS Group held 225,624 shares of Theriva Biologics worth $44.2K as of Q1 2026.
  • UBS Group bought 34,214 Theriva Biologics shares in Q1 2026, an estimated $6.74K.
  • Theriva Biologics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7450 holding.
  • UBS Group first reported a position in Theriva Biologics in Q4 2014 and has held it in 37 quarters since.
  • UBS Group's Theriva Biologics position peaked at $680K in Q1 2016.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.